Top

Published in:

01-06-2001 | Original Research Article

International Validation of the CLAU-S Quality-of-Life Questionnaire for Use in Patients with Intermittent Claudication

Authors: Patrick Marquis, Dr Sylvie Comte, Philippe Lehert

Published in: PharmacoEconomics | Issue 6/2001

Abstract

Background: Intermittent claudication (IC) occurs in patients with peripheral occlusive arterial disease and results in leg pain after walking a certain distance — the claudication distance. Until recently, no specific questionnaire has been available to measure quality of life in patients with IC.

Objectives: To validate the Claudication Scale (CLAU-S) questionnaire in patients in France, the UK, Germany and Belgium.

Methods: Patients completed the CLAU-S questionnaire and provided demographic and clinical data. Pooled data were examined for psychometric and structural validity and test-retest reliability. Structural equation modelling (SEM) was used to confirm that the questionnaire was measuring the causal relationships involved in IC in each of the language groups studied.

Results: Cross-sectional and factor analysis confirmed the validity of the questionnaire in the pooled patient population. Item convergent and discriminant coefficients and internal consistency reliability coefficients met or exceeded standard criteria. Principal component analysis confirmed the factorial structure. The underlying causal relationships in IC were identified using SEM and were consistent in all language groups studied.

Conclusions: The CLAU-S questionnaire has undergone validation in English, French, German and Flemish and has a very satisfactory validity in these languages.

Kannel WB, Shurtleff D. The Framington study: cigarettes and the development of intermittent claudication. Geriatrics 1973; 28: 61–8PubMed

Klannel WB, D’Agostino RB, Wilson PW, et al. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framington experience. Am Heart J 1990; 120: 672–6CrossRef

Murabito JM, D’Agostino RB, Silbershatz H, et al. Intermittent claudication: a risk profile from The Framington Heart Study. Circulation 1997; 96: 44–9PubMedCrossRef

Johansson J, Egberg N, Hohnsson H, et al. Serum lipoproteins and hemostatic function in intermittent claudication. Arterioscler Thromb 1993; 13: 1441–8PubMedCrossRef

Dormandy JA, Hoare E, Khattab AH, et al. Prognostic significance of rheological and biochemical findings in patients with intermittent claudication. BMJ 1973; 4: 581–3PubMedCrossRef

Molgaard J, Malinow MR, Lassvik C, et al. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Intern Med 1992; 231: 273–9PubMedCrossRef

Arfvidsson B, Karlsson J, Dahllof AG, et al. The impact of intermittent claudication on quality of life evaluated by the Sickness Impact Profile technique. Eur J Clin Invest 1993; 23 (11): 741–5PubMedCrossRef

Pell JP. Impact of intermittent claudication on quality of life. The Scottish Vascular Audit Group. Eur J Vasc Endovasc Surg 1995; 10 (4): 510–1CrossRef

Currie IC, Wilson YG, Baird RN, et al. Treatment of intermittent claudication: the impact on quality of life. Eur J Vasc Endovasc Surg 1995; 10 (3): 356–61PubMedCrossRef

10.

Khaira HS, Hanger R, Shearman CP. Quality of life in patients with intermittent claudication. Eur J Vasc Endovasc Surg 1996; 12 (4): 511–2CrossRef

11.

Ponte E, Cattinelli S. quality of life in a group of patients with intermittent claudication. Angiology 1996; 47 (3): 247–51PubMedCrossRef

12.

Finger T, Kirchberger I, Dietze S, et al. Assessing the quality of life of patients with intermittent claudication: psychometric properties of the claudication scale (CLAU-S) [abstract]. Qual Life Res 1995; 4 (5): 427

13.

Dietze S, Kirchberger I, Spengel F, et al. Die claudicatio-scala (CLAU-S) ein krankheitsspezifischer fragebogen zur erfassung der lebensqualitat von patienten mit claudicatio intermitten, entwicklung und validier. Gefäßchirurgie 1997; 2: 11–7CrossRef

14.

Acquadro C, Jambon B, Ellis D, et al. Language and translation issues. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996: 575–85

15.

Spengel F, Brown TM, Dietze S, et al. The claudication scale (CLAU-S): a new disease-specific quality-of-life instrument in intermittent claudication. Dis Manage Health Outcomes 1997; 2 Suppl. 1: 65–70CrossRef

16.

Liard F, Benichou AC, Gamand S, et al. Les effets du naftidrofuryl sur la qualite de vie. Dis Manage Health Outcomes 1997; 2 Suppl. 1: 71–8CrossRef

17.

Spengel F, Brown TM, Poth J, et al. Naftidrofuryl can enhance the quality of life in patients with intermittent claudication. Vasa 1999; 28: 207–12PubMedCrossRef

18.

Leidy NK, Revicki DA, Genesté B. Recommendations for evaluating the validity of quality of life claims for labelling and promotion. Values Health 1999; 2 (2): 113–27CrossRef

19.

Lohr KN, Aaronson NK, Alonso J, et al. Evaluating quality-of-life and health status instruments: development of scientific review criteria. Clin Ther 1996; 18 (5): 979–92PubMedCrossRef

20.

Van de Vijver F, Leung K. Methods and data analysis for cross-cultural research. Thousand Oaks: Sage Publications, 1997

21.

Hays R, Anderson R, Revicki DA. Assessing reliability and validity of measurement in clinical trials. In: Staquet MJ, Hays RD, Fayers PM, editors. Quality of life assessment in clinical trials. New York: Oxford University Press, 1998: 169–82

22.

Nunnally J. Psychometric theory. New York: McGraw Hill, 1978

23.

Bollen KA. Structural equation with latent variables. New York: J Wiley, 1989

24.

Keller SD, Ware Jr JE, Bentler PM, et al. Use of structural equation modeling to test the construct validity of the SF-36 health survey in 10 countries: results from the IQOLA project. International quality of Life Assessment. J Clin Epidemiol 1998; 51: 1179–88PubMedCrossRef

25.

Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures: statistics and strategies for evaluation. Control Clin Trials 1991; 12 (4 Suppl.): S142–58CrossRef

26.

Lehert P. quality of life assessment in comparative therapeutic trials and causal structure considerations: the particular case of peripheral occlusive arterial disease. Pharmacoeconomics 2001; 19 (2): 121–30PubMedCrossRef

27.

Boccalon H, Lehert P, Mosnier M. Appréciation de la prévalence de l’arthériopathie oblitérante des membres inferieurs en France à l’aide de l’index systolique dans une population à risque vasculaire. J Mal Vasc 2000; 25: 38–46PubMed

28.

Balkau B, Vray M, Eschwege E. Epidemiology of peripheral arterial disease. J Cardiovasc Pharmacol 1994; 23 Suppl. 3: S8–16

29.

Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996; 25 (6): 1172–81PubMedCrossRef

30.

Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA 1995; 273 (1): 59–65PubMedCrossRef

31.

World Health Organisation [online]. Available from URL: http://www.who.int/ [Accessed 2001 May 4]

Title: International Validation of the CLAU-S Quality-of-Life Questionnaire for Use in Patients with Intermittent Claudication
Authors: Patrick Marquis
Dr Sylvie Comte
Philippe Lehert
Publication date: 01-06-2001
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 6/2001
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200119060-00005

Keynote webinar | Spotlight on medication adherence

Springer Medicine

International Validation of the CLAU-S Quality-of-Life Questionnaire for Use in Patients with Intermittent Claudication

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2001

An Economic Overview of Chronic Obstructive Pulmonary Disease

An Epidemiological Approach to Assess the Economic Burden of NSAID-Induced Gastrointestinal Events in The Netherlands

Quality of Life in Irritable Bowel Syndrome

Developing Guidance for Budget Impact Analysis

Torasemide